- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04752631
MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK)
July 31, 2022 updated by: Hui-Sheng Chen, General Hospital of Shenyang Military Region
MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study
This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis for stroke beyond time window by Tenecteplase (TNK-tPA).
This exploratory study was to describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia.
Study Overview
Detailed Description
In patients with acute stroke with an unknown time of onset, intravenous alteplase guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia resulted in a significantly better functional outcome at 90 days.
This trial will enroll acute ischemic stroke patients within 4.5 to 24 hours of onset.
All the patients had an ischemic lesion that was visible on MRI diffusion-weighted imaging but no parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR), which indicated that the stroke had a ischemic penumbra.
Randomization will be 1:1 to TNK-tPA (experimental) or standard treatment (control), in compliance with guidelines for acute stroke.
Clinical outcome was assessed by disability on the basis of the modified Rankin scale at 90 days follow-up, which will be performed by a blinded assessor.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shenyang, China, 110016
- Department of Neurology, General Hospital of Northern Theater Command
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient age 18-80 years;
- The time from onset to treatment: 4.5-24 hours;
- Acute Ischemic stroke confirmed by MRI;
- NIHSS score :6-25, or NIHSS score≤ 5 but culprit vessel occlusion or severe stenosis ( ICA, MCA-M1/M2, ACA) on CTA/MRA;
- Imaging requirements: (1) DWI infarct region: no more than 1/3 of middle cerebral artery territory or 1/2 of the anterior cerebral artery territory or 1/2 of the posterior cerebral artery territory; (2) DWI infarct volume <70 ml; (2) presence of DWI/Flair mismatch: DWI high signal and Flair visually normal;
- the first onset of ischemic stroke or previous stroke with no obvious sequelae (mRS≤1);
- Signed informed consent
Exclusion Criteria:
- Planned endovascular treatment;
- Serious neurological deficits before onset ( mRS ≥ 2);
- Obvious head injuries or strokes within 3 months;
- Subarachnoid hemorrhage;
- History of intracranial hemorrhage;
- Intracranial tumor, arteriovenous malformation or aneurysm;
- Intracranial or spinal cord surgery within 3 months;
- Arterial puncture at a noncompressible site within the previous seven days;
- Active internal hemorrhage;
- coagulation abnormalities: platelet count of <100000/mm3 ;
- Aortic arch dissection;
- Heparin therapy within 24 hours;
- Infective endocarditis;
- Oral warfarin is being taken and INR>1.6 or APTT abnormal;
- oral anticoagulation therapy;
- Systolic pressure ≥185 mmHg or diastolic pressure ≥110 mmHg;
- Blood glucose < 50 mg/dl (2.7mmol/L);
- Pregnancy;
- Neurological deficit after epileptic seizures;
- Major surgery within 1 month;
- Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
- Myocardial infarction within 3 months;
- allergy to study drugs;
- Contradictory to MRI examination;
- MRI image not qualified for evaluation;
- Other serious illness;
- Participating in other clinical trials within 3 months;
- patients not suitable for this clinical studies considered by researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TNK-tPA
TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.
|
The participants received TNK-tPA thrombolytic therapy
Other Names:
|
No Intervention: Routine Therapy
Patients will be treated with standard of care in compliance with guidelines for acute stroke
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of modified Rankin Scale (mRS) 0-1
Time Frame: 90 Days
|
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
|
90 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of modified Rankin Scale (mRS) 0-2
Time Frame: 90 Days
|
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
|
90 Days
|
Distribution of the modified Rankin Scale (mRS)
Time Frame: 90 Days
|
the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome
|
90 Days
|
Changes in National Institute of Health stroke scale (NIHSS)
Time Frame: 24 hours and 1 week
|
the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome
|
24 hours and 1 week
|
vascular events
Time Frame: 90 Days
|
The incidence of stroke and other vascular events
|
90 Days
|
proportion of death
Time Frame: 14 days
|
death due to any cause
|
14 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of symptomatic intracranial hemorrhage (sICH)
Time Frame: 48 hours
|
sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
|
48 hours
|
Proportion of intraparenchymal hemorrhage (PH1 and PH2)
Time Frame: 48 hours
|
Proportion of PH1 and PH2 within 48 hours after the treatment
|
48 hours
|
proportion of hemorrhagic transformation
Time Frame: 7 Days
|
Intracranial hemorrhage assessed by MRI/CT
|
7 Days
|
any bleeding events
Time Frame: 7 Days
|
proportion of any bleeding events
|
7 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Chen Hui-Sheng, Doctor, General Hospital of Shenyang Military Region
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2021
Primary Completion (Actual)
July 24, 2022
Study Completion (Actual)
July 24, 2022
Study Registration Dates
First Submitted
February 9, 2021
First Submitted That Met QC Criteria
February 9, 2021
First Posted (Actual)
February 12, 2021
Study Record Updates
Last Update Posted (Actual)
August 2, 2022
Last Update Submitted That Met QC Criteria
July 31, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Y(2020)067
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Tenecteplase
-
Kaiser PermanenteGenentech, Inc.TerminatedPleural EffusionUnited States
-
Huashan HospitalShanghai 10th People's Hospital; Shanghai East Hospital; The Second Affiliated... and other collaboratorsCompleted
-
Boehringer IngelheimTerminatedHeart ArrestGermany, Belgium, Sweden, France, Austria, Italy, Norway, Spain, Switzerland
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
University Of PerugiaTerminated
-
The George InstituteUniversity of Calgary; Berry ConsultantsNot yet recruiting
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
Genentech, Inc.CompletedDysfunctional Hemodialysis Catheters
-
General Hospital of Shenyang Military RegionCompleted
-
Second Affiliated Hospital of Guangxi Medical UniversityCSPC Pharmaceutical Group LimitedNot yet recruiting